Pennsylvania Filed for $400 Million Drug Settlement
The agreement resolves allegations that two pharmaceutical companies conspired to inflate generic drug prices.
Updated on Oct. 2, 2026 in Healthcare
Live Poll
Should pharmaceutical companies face financial penalties for manipulating generic drug prices?
Pennsylvania Attorney General Dave Sunday has filed for preliminary approval of a $400 million settlement with Sandoz Inc. and Fougera Pharmaceuticals Inc. The state expects to receive more than $14.8 million from the deal.
Why it matters
The settlement addresses claims that the companies engaged in conspiracies to artificially inflate prices and reduce competition for generic drugs. It serves as a resolution to allegations against both the companies and their international affiliates.
The proposed settlement totals $400 million, with Pennsylvania set to receive more than $14.8 million. Consumers who purchased specific generic drugs between May 2009 and December 2019 may be eligible for compensation.
The players
Dave Sunday
Dave Sunday is the Attorney General of Pennsylvania who filed the motion for preliminary approval of the settlement.
Sandoz Inc.
Sandoz Inc. is a pharmaceutical company that agreed to the settlement and promised to implement internal reforms.
Fougera Pharmaceuticals Inc.
Fougera Pharmaceuticals Inc. is a pharmaceutical company involved in the settlement regarding allegations of price manipulation.
The details
The settlement resolves allegations that Sandoz and Fougera manipulated generic drug pricing to curb competition. As part of the agreement, Sandoz has committed to implementing internal reforms designed to ensure strict compliance with federal antitrust laws.
Timeline
May 2009 marks the start date for eligible generic drug purchases.
December 2019 marks the end date for eligible generic drug purchases.
October 2026 is when the motion for settlement approval was filed.
Market Landscape
This action aligns with the broader push to enforce fair competition under the Sherman Antitrust Act. It signals an increased focus by state regulators on holding pharmaceutical companies accountable for pricing strategies that stifle market competition.
Consumers who purchased listed generic drugs during the specified decade may be eligible for compensation. Residents can learn more by calling the toll-free eligibility phone number 1-866-290-0182.
The takeaway
This settlement provides a path for restitution to residents impacted by years of inflated generic drug costs. It also mandates that Sandoz change its internal procedures to prevent future antitrust violations.
Further reading
For additional context on how state litigation impacts the industry, explore our Healthcare section.
More information
To verify if you qualify for compensation, visit the Settlement eligibility and claims portal.
Live Poll
Should pharmaceutical companies face financial penalties for manipulating generic drug prices?
